Could Akebia Therapeutics Inc (NASDAQ:AKBA) Skyrocket? The Stock Had Too Little Sellers

April 17, 2018 - By Migdalia James

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Investors sentiment decreased to 1.63 in Q4 2017. Its down 0.60, from 2.23 in 2017Q3. It fall, as 15 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 26 funds opened positions while 44 raised stakes. 30.27 million shares or 5.16% more from 28.78 million shares in 2017Q3 were reported.
Alliancebernstein L P accumulated 43,200 shares. Invesco Ltd reported 0% stake. Mississippi-based Hancock Com has invested 0.04% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Plante Moran Advsr Lc owns 1,500 shares for 0.01% of their portfolio. Panagora Asset reported 146,544 shares. Northern Trust owns 513,456 shares. Rhumbline Advisers has 40,772 shares. Aqr Capital Mgmt Limited Liability Com invested 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Federated Pa holds 0% or 266 shares in its portfolio. State Board Of Administration Of Florida Retirement System holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 14,169 shares. 7,600 are owned by Us Comml Bank De. First Manhattan holds 0.05% or 565,066 shares in its portfolio. Moreover, Mutual Of America Capital Mgmt Lc has 0.03% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 130,179 shares. Blackrock Inc has 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 3.91 million shares. Trexquant Investment L P owns 21,102 shares.

Since February 15, 2018, it had 0 buys, and 1 sale for $14,620 activity.

The stock of Akebia Therapeutics Inc (NASDAQ:AKBA) registered a decrease of 0.36% in short interest. AKBA’s total short interest was 4.11M shares in April as published by FINRA. Its down 0.36% from 4.12M shares, reported previously. With 837,300 shares average volume, it will take short sellers 5 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Inc’s float is 25.66%.

The stock decreased 1.01% or $0.1 during the last trading session, reaching $9.85. About 129,739 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 5.85% since April 17, 2017 and is uptrending. It has underperformed by 5.70% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $552.71 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

Among 4 analysts covering Akebia Therapeutics (NASDAQ:AKBA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Akebia Therapeutics had 4 analyst reports since November 2, 2017 according to SRatingsIntel. The rating was initiated by Piper Jaffray on Monday, December 18 with “Buy”. The firm has “Buy” rating by BTIG Research given on Thursday, December 7. The firm has “Buy” rating given on Wednesday, March 7 by Mizuho. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: